Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00776594 · ClinicalTrials.gov registry record · Phase 2
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT00776594 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 102 participants.
The verdict
NCT00776594, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of this research study is to assess the efficacy of antiangiogenic therapy (bevacizumab) and androgen deprivation versus androgen deprivation alone at the time of minimal systemic disease (based on rising PSA without metastases).
Interventions
- DRUG Androgen Deprivation Therapy
- DRUG bevacizumab
- DRUG bicalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2008-10 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00776594
The ClinicalTrials.gov registry entry for NCT00776594 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Androgen Deprivation Therapy is the first listed.
NCT00776594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00776594 about?
NCT00776594 is a clinical study titled "Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy". The purpose of this research study is to assess the efficacy of antiangiogenic therapy (bevacizumab) and androgen deprivation versus androgen deprivation alone at the time of minimal systemic disease (based on rising PSA without metastases).
What is the current status of trial NCT00776594?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2008-10. Estimated completion is 2016-09.
What interventions are being tested in trial NCT00776594?
The interventions under investigation include: Androgen Deprivation Therapy (DRUG), bevacizumab (DRUG), bicalutamide (DRUG).
Who is sponsoring clinical trial NCT00776594?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.